March 6, 2012 – Phylonix today announced issuance of EU Patent EP 1878 799 B1 "Methods of Screening Agents for Activity Using Teleosts". This broad patent claims performing drug screening in microplates. The patent also claims use of automated instrumentation to screen agents for activity in zebrafish. In addition, the patent claims use of microplates and automated methods for assessing compound induced toxicity, cell death and angiogenesis.
Phylonix, located in Cambridge, MA, is a Contract Research Organization developing and marketing patented, in vivo zebrafish-based assays, eZ-Screens™, for assessing drug candidates for cancers, central nervous system disorders, cardiovascular diseases, apoptosis, and organ toxicity. The company also offers services for target identification and validation. Partnerships are available for these services as well as for drug repositioning candidates that fail clinical trials for an initial indication. Services are tailored for several industry sectors including: agrochemicals, biotechnology, pharmaceuticals, nutraceuticals, environmental and other government agencies, as well as general safety liability. For information on licensing options contact Edward O’Lear, Vice President of Finance and Business Development at firstname.lastname@example.org or 617-441-6700 ex 302.<<Back to Home Page